|
Antibody |
# patients reported |
Identified by more that one laboratory |
Paraneoplastic neurological syndrome |
Tumors |
% of antibody positive patients without cancer 1 (# of patients
studied) |
Frecuency in isolated cancer (# studied) |
| Anti-Yo (PCA1) |
>200 |
Yes |
Paraneoplastic cerebellar degeneration (PCD) |
Ovary, breast |
4% (125) |
1% (107) |
| Anti-Hu (ANNA1) |
>600 |
Yes |
Sensory neuronopathy Encephalomyelitis Chronic pseudoobstruction PCD Limbic encephalitis |
Small-cell lung cancer (SCLC) |
2% (200) |
16% (196) (1% with titers
similar to those patients with PNS) |
| Anti-CV2(CRMP5) |
>100 |
Yes |
Chorea Sensory neuronopathy Sensorimotor neuropathy Encephalomyelitis Chronic pseudoobstruction PCD Limbic encephalitis |
SCLC, thymoma |
4% (47) |
9% (74) |
| Anti-Ri (ANNA2) |
50 |
Yes |
Brainstem encephalitis |
Breast, SCLC |
9% (22) |
4% (181 ovarian cancer) |
| Anti-Ma2 |
18 |
Yes |
Limbic/mesodiencephalic
encephalitis |
Testicular |
0% (18) |
0% (175) |
| Anti-amphiphysin |
13 |
Yes |
Stiff-person syndrome Various syndromes |
Breast SCLC |
0% (10) |
0% (25 breast, ovary) 1%(146 SCLC) |
| Anti-Tr (PCA-Tr) |
28 |
Yes |
PCD |
Hodgkin’s disease |
11% (28) |
0% (30) |
| Anti-Ma |
11 |
Yes |
Brainstem encephalitis/PCD |
Various tumors |
10% (11) |
0% (175) |
| Anti-ANNA3 |
11 |
No |
Various syndromes |
SCLC |
9% (11) |
? |
| Anti-PCA2 |
9 |
No |
Various syndromes |
SCLC |
0% (8) |
2% (58) |
| Anti-Zic |
8 |
No |
PCD |
SCLC |
12% (8) |
16% (74) |
|
Anti-mGluR1 |
2 |
No |
PCD |
Hodgkin’s disease |
50% (2) |
? |
1 Defined by number
of patients with follow-up of more than 3 years and no tumor
found